The FDA has approved Novartis’ NDA218276 for FABHALTA (iptacopan hydrochloride), an oral drug ultimately aiming to disrupt the complement cascade. This approval positions Novartis to aggressively defend its market share against BeiGene’s Farxiga in the chronic kidney disease space.